Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Jurnista | Hydromorphone hydrochloride | Pain, Chronic (moderate to severe) | Do not list | Complete | ||
| Isentress | Raltegravir | HIV (treatment naïve) | Do not list | Complete | ||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis (in women), Severe | Do not list | Complete | ||
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Spasticity, Post-stroke | Do not list | Complete | ||
| Silkis | Calcitriol | Psoriasis, mild to moderate plaque | Do not list | Complete | ||
| Effient | Prasugrel hydrochloride | Acute Coronary Syndrome | Do not list | Complete | ||
| Ilaris | Canakinumab | Cryopyrin-Associated Periodic Syndrome | Do not list | Complete | ||
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Do not list | Complete | ||
| Invega Sustenna | Paliperidone palmitate | Schizophrenia | Do not list | Complete | ||
| Victoza | Liraglutide | Diabetes mellitus, Type 2 | Do not list | Complete |
Last Updated : May 13, 2024